Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221501 | 0.87 | CYP11B1 (0.40) | NLRP3CYP11B1CYP11B2LTB4R2PTPN11 | |
| SCHEMBL12191932 | 0.84 | CYP1A2 (0.46) | CYP11B1CYP11B2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12191895 | 0.83 | MEN1 (0.37) | PPARGAGTR2PTPN11CNR2 | |
| SCHEMBL12968482 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL20782276 | 0.76 | GABRA1 (0.46) | PPARGCYP11B1CYP11B2LTB4RCYP1A2 | |
| SCHEMBL12192913 | 0.75 | FFAR1 (0.38) | — | |
| SCHEMBL2500615 | 0.74 | FFAR1 (0.54) | — | |
| SCHEMBL2499268 | 0.74 | FFAR1 (0.54) | — | |
| SCHEMBL12192810 | 0.73 | SIGMAR1 (0.37) | — | |
| SCHEMBL11996441 | 0.73 | TAAR1 (0.39) | PPARGCYP11B1CYP11B2LTB4R2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | PPARG 13/4885NLRP3 1845/4885AGTR2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.